Clinical trialNARecruiting
Evaluating Intermittent Fasting In Individuals At High Risk ForPancreatic Cancer Undergoing Screening
- Outcome
- Ongoing
- Phase
- NA
- Status
- Recruiting
- Study type
- Interventional
- Start
- 10 June 2026
- Expected end
- 30 March 2029
- Enrollment
- 20 participants
- Sites
- 1
- Primary outcomes
- Safety and adverse events (AEs).
- Sponsor
- Other
- Results posted
- No
- Last update
- 14 October 2026
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
To learn whether an eating pattern called intermittent fasting (IF) is tolerable and feasible for individuals at high risk of pancreatic cancer and whether IF is associated with changes in biological markers, including metabolic, inflammatory, microbiome, and imaging-related markers.
Detailed description public domain (ClinicalTrials.gov)
Primary Objectives • To assess the tolerability and feasibility of Intermittent fasting (IF) in participants at high risk for pancreatic cancer. Secondary Objectives * To assess changes in oral and gut microbiome after IF. * To assess changes in metabolomic markers after IF. * To assess changes in inflammatory markers after IF.
Intervention public domain (ClinicalTrials.gov)
Other: intermittent fasting. They will fast for 16 consecutive hours each day and have an 8-hour window for eating.
Arm public domain (ClinicalTrials.gov)
Intermittent fasting (experimental): Fast for 16 consecutive hours each day and have an 8-hour window for eating.
Primary outcome public domain (ClinicalTrials.gov)
Safety and adverse events (AEs).. Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 Time frame: Through study completion; an average of 1 year..
Eligibility public domain (ClinicalTrials.gov)
Inclusion Criteria * Participants ≥ 18 years old. Participants under 18 are excluded due to their potential inability to understand and consent independently to the methods required for the study drug use and its potential risks and benefits. * Participants evaluated and classified as high risk for pancreatic cancer through a High-Risk Pancreatic Cancer Clinic or High-Risk Pancreatic Cyst Clinic, based on established clinical assessment and risk stratification. * High-risk status may include one or more of the following: * Hereditary cancer syndromes or known pathogenic germline mutations associated with pancreatic cancer risk * Family history of pancreatic ductal adenocarcinoma (PDAC) * Presence of pancreatic cysts or precursor lesions (e.g., IPMN, MCN) * New-onset diabetes mellitus is considered suspicious for pancreatic cancer * History of recurrent or chronic pancreatitis * Eligibility and surveillance risk assessment must be consistent with NCCN (National Comprehensive Cancer Network) Guidelines for Pancreatic Cancer Screening in High- Risk Individuals. * Participants are able to understand and are willing to sign a written informed consent document. * Both English-speaking and non-English-speaking participants are eligible for participation * Participants are willing to make a change in eating time patterns. * Participants are willing to provide App-tracked fasting time data over the course of the study. Exclusion Criteria * BMI \< 18.5 Kg/m2 * Documented history of symptomatic hypoglycemia * Pregnant or breastfeeding women * Cognitively impaired individuals
Enrollment public domain (ClinicalTrials.gov)
Enrollment: 20 participants (estimated).